EFFECTS OF NAAG AND MPEP ON RAT CORTICAL SPREADING DEPRESSION

ZHEN WANG; WEIHUA LUO; XIAOLI SUN; PENGCHENG LI; SHANGBIN CHEN; QINGMING LUO

doi:10.1142/s1793545810000939

[1] J. M. Smith, D. P. Bradley, M. F. James, C. L. Huang, “Physiological studies of cortical spreading depression,” Biol. Rev. Camb. Philos. Soc. 81, 457– 481 (2006).

[2] G. G. Somjen, “Mechanisms of spreading depression and hypoxic spreading depression-like depolarization,” Physiol. Rev. 81, 1065–1096 (2001).

[3] J. Zhou, J. H. Neale, M. G. Pomper, A. P. Kozikowski, “NAAG peptidase inhibitors and their potential for diagnosis and therapy,” Nat. Rev. Drug Discov. 4, 1015–1026 (2005).

[4] M. Lauritzen, A. J. Hansen, “The effect of glutamate receptor blockade on anoxic depolarization and cortical spreading depression,” J. Cereb. Blood Flow Metab. 12, 223–229 (1992).

[5] M. Lauritzen, “Pathophysiology of the migraine aura. The spreading depression theory,” Brain 117(Pt 1), 199–210 (1994).

[6] C. Ayata, M. A. Moskowitz, “Cortical spreading depression confounds concentration-dependent pial arteriolar dilation during N-methyl-d-aspartate superfusion,” Am. J. Physiol. Heart Circ. Physiol. 290, 1837–1841 (2006).

[7] R. Marrannes, R. Willems, E. De Prins, A. Wauquier, “Evidence for a role of the N-methyld- aspartate (NMDA) receptor in cortical spreading depression in the rat,” Brain Res. 457, 226–240 (1988).

[8] H. Kruger, U. Heinemann, H. J. Luhmann, “Effects of ionotropic glutamate receptor blockade and 5- HT1A receptor activation on spreading depression in rat neocortical slices,” Neuroreport 10, 2651–2656 (1999).

[9] B. Nellgard, T. Wieloch, “NMDA-receptor blockers but not NBQX, an AMPA-receptor antagonist, inhibit spreading depression in the rat brain,” Acta Physiol. Scand. 146, 497–503 (1992).

[10] D. D. Mitsikostas, M. S. del Rio, C. Waeber, Z. Huang, F. M. Cutrer, M. A. Moskowitz, “Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis,” Br. J. Pharmacol. 127, 623–630 (1999).

[11] Z. X. Xi, M. Kiyatkin, X. Li, X. Q. Peng, A. Wiggins, K. Spiller, J. Li, E. L. Gardner, “N-acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self-administration and cocaineenhanced brain-stimulation reward in rats,” Neuropharmacology 58, 304–313 (2010).

[12] T. Yamamoto, A. Kozikowski, J. Zhou, J. H. Neale, “Intracerebroventricular administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain,” Mol. Pain 4, 31 (2008).

[13] Z. Cai, S. Lin, P. G. Rhodes, “Neuroprotective effects of N-acetylaspartylglutamate in a neonatal rat model of hypoxia-ischemia,” Eur. J. Pharmacol. 437, 139–145 (2002).

[14] S. Ghose, K. A. Gleason, B. W. Potts, K. Lewis- Amezcua, C. A. Tamminga, “Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: A mechanism for antipsychotic drug action ” Am. J. Psychiatry 166, 812–820 (2009).

[15] V. Bruno, I. Ksiazek, G. Battaglia, S. Lukic, T. Leonhardt, D. Sauer, F. Gasparini, R. Kuhn, F. Nicoletti, P. J. Flor, “Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective,” Neuropharmacology 39, 2223–2230 (2000).

[16] A. Gorji, “Spreading depression: A review of the clinical relevance,” Brain Res. Rev. 38, 33–60 (2001).

[17] A. M. Ba, M. Guiou, N. Pouratian, A. Muthialu, D. E. Rex, A. F. Cannestra, J. W. Chen, A. W. Toga, “Multiwavelength optical intrinsic signal imaging of cortical spreading depression,” J. Neurophysiol. 88, 2726–2735 (2002).

[18] A. Van Hemelrijck, S. Hachimi-Idrissi, S. Sarre, G. Ebinger, Y. Michotte, “Neuroprotective effect of Nacetyl- aspartyl-glutamate in combination with mild hypothermia in the endothelin-1 rat model of focal cerebral ischemia,” J. Neurochem. 95, 1287–1297 (2005).

[19] C. Bellone, C. Luscher, M. Mameli, “Mechanisms of synaptic depression triggered by metabotropic glutamate receptors,” Cell Mol. Life Sci. 65, 2913–2923 (2008).

[20] S. Chen, P. Li, W. Luo, H. Gong, S. Zeng, Q. Luo, “Origin sites of spontaneous cortical spreading depression migrated during focal cerebral ischemia in rats,” Neurosci. Lett. 403, 266–270 (2006).

[21] Z. Wang, P. Li, W. Luo, S. Chen, Q. Luo, “Periinfarct temporal changes in intrinsic optical signal during spreading depression in focal ischemic rat cortex,” Neurosci. Lett. 424, 133–138 (2007).

[22] T. A. Basarsky, S. N. Duffy, R. D. Andrew, B. A. MacVicar, “Imaging spreading depression and associated intracellular calcium waves in brain slices,” J. Neurosci. 18, 7189–7199 (1998).

[23] M. Guiou, S. Sheth, M. Nemoto, M. Walker, N. Pouratian, A. Ba, A. W. Toga, “Cortical spreading depression produces long-term disruption of activity-related changes in cerebral blood volume and neurovascular coupling,” J. Biomed. Opt. 10, 11004 (2005).

[24] J. H. Neale, R. T. Olszewski, L. M. Gehl, B. Wroblewska, T. Bzdega, “The neurotransmitter Nacetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia,” Trends Pharmacol. Sci. 26, 477–484 (2005).

[25] F. Richter, A. Lehmenkuhler, “[Cortical spreading depression (CSD): A neurophysiological correlate of migraine aura],” Schmerz 22, 544–546, 548–550 (2008).

[26] D. Pietrobon, “Familial hemiplegic migraine,” Neurotherapeutics 4, 274–284 (2007).

[27] C. Ayata, M. Shimizu-Sasamata, E. H. Lo, J. L. Noebels, M. A. Moskowitz, “Impaired neurotransmitter release and elevated threshold for cortical spreading depression in mice with mutations in the alpha1A subunit of P/Q type calcium channels,” Neuroscience 95, 639–645 (2000).

[28] T. Horiguchi, B. Kis, N. Rajapakse, K. Shimizu, D. W. Busija, “Cortical spreading depression (CSD)-induced tolerance to transient focal cerebral ischemia in halothane anesthetized rats is affected by anesthetic level but not ATP-sensitive potassium channels,” Brain Res. 1062, 127–133 (2005).

[29] N. Cholet, L. Pellerin, P. J. Magistretti, E. Hamel, “Similar perisynaptic glial localization for the Na+, K+-ATPase alpha 2 subunit and the glutamate transporters GLAST and GLT-1 in the rat somatosensory cortex,” Cereb. Cortex 12, 515–525 (2002).

[30] A. Simonyi, T. R. Schachtman, G. R. Christoffersen, “The role of metabotropic glutamate receptor 5 in learning and memory processes,” Drug News Perspect. 18, 353–361 (2005).

[31] P. M. Lea, A. I. Faden, “Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP,” CNS Drug Rev. 12, 149–166 (2006).

[32] P. Malherbe, N. Kratochwil, M. T. Zenner, J. Piussi, C. Diener, C. Kratzeisen, C. Fischer, R. H. P. Porter, “Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl- 6-(phenylethynyl)-pyridine,” Mol. Pharmacol. 64, 823 (2003).

[33] W. P. Spooren, F. Gasparini, T. E. Salt, R. Kuhn, “Novel allosteric antagonists shed light on mglu (5) receptors and CNS disorders,” Trends Pharmacol. Sci. 22, 331–337 (2001).